Value‑Based Contracting for Cell and Gene Therapies: A Scoping Review of Payer-Manufacturer Agreements and Treatment‑Center Considerations in USA
{{output}}
Background: Cell and gene therapies (CGTs) offer the potential for durable or curative outcomes, but come with high upfront costs and uncertainty about long-term safety and effectiveness. To address these challenges, manufacturer... ...
